The Cure CJD Campaign
@curecjdcampaign.bsky.social
To find a cure for fatal prion diseases (CJD, GSS, IFF) and raise funds for PRN100 clinical trial phase II. With your support it will happen! curecjd.org
“We are filled with hope to support such a promising treatment that could halt these terrifying and fatal diseases and contribute to the fight against other neurodegenerative conditions.” Charlotte, Chair of @curecjdcampaign.bsky.social
@geneticallianceuk.bsky.social
@cjdsupport.bsky.social
@geneticallianceuk.bsky.social
@cjdsupport.bsky.social
November 12, 2025 at 2:39 PM
“We are filled with hope to support such a promising treatment that could halt these terrifying and fatal diseases and contribute to the fight against other neurodegenerative conditions.” Charlotte, Chair of @curecjdcampaign.bsky.social
@geneticallianceuk.bsky.social
@cjdsupport.bsky.social
@geneticallianceuk.bsky.social
@cjdsupport.bsky.social
The Lancet article also suggests a future role of PRN100 for treatment of Alzheimer’s disease and possibly other common neurodegenerative diseases.
#alzheimer #parkinson #prionlikedisease
@thelancet.com
@alzheimerssoc.bsky.social
#alzheimer #parkinson #prionlikedisease
@thelancet.com
@alzheimerssoc.bsky.social
November 12, 2025 at 2:39 PM
The Lancet article also suggests a future role of PRN100 for treatment of Alzheimer’s disease and possibly other common neurodegenerative diseases.
#alzheimer #parkinson #prionlikedisease
@thelancet.com
@alzheimerssoc.bsky.social
#alzheimer #parkinson #prionlikedisease
@thelancet.com
@alzheimerssoc.bsky.social
PRN100 was administrated to 6 patients with CJD in a small treatment programme.
The Lancet described results as very encouraging, concluding that formal Phase II trial is now needed to confirm treatment’s efficacy.
thelancet.com/article/S147...
@thelancet.com
@smead2.bsky.social
@MRC_UK
The Lancet described results as very encouraging, concluding that formal Phase II trial is now needed to confirm treatment’s efficacy.
thelancet.com/article/S147...
@thelancet.com
@smead2.bsky.social
@MRC_UK
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme
Our academic-led programme delivered what is, to our knowledge, the first rationally
designed experimental treatment for human prion disease to a small number of patients
with CJD. The treatment appea...
thelancet.com
November 12, 2025 at 2:39 PM
PRN100 was administrated to 6 patients with CJD in a small treatment programme.
The Lancet described results as very encouraging, concluding that formal Phase II trial is now needed to confirm treatment’s efficacy.
thelancet.com/article/S147...
@thelancet.com
@smead2.bsky.social
@MRC_UK
The Lancet described results as very encouraging, concluding that formal Phase II trial is now needed to confirm treatment’s efficacy.
thelancet.com/article/S147...
@thelancet.com
@smead2.bsky.social
@MRC_UK